A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia

Benzer Materyaller

• Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia
  Yazar:: Wei, Guoqing, ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• Successful treatment of relapsed acute B-cell lymphoblastic leukemia with CD20/CD22 bispecific chimeric antigen receptor T-cell therapy
  Yazar:: Liang, Zuyu, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
  Yazar:: Dai, Hanren, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Factors Associated with Costs in Chimeric Antigen Receptor T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies
  Yazar:: Zhu, Feng, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
  Yazar:: Dai, Hanren, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)